Trial Profile
A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Salmeterol/fluticasone propionate (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Acronyms DISARM
- 31 Aug 2021 Status changed from recruiting to completed, according to Results published in the American Journal of Respiratory and Critical Care Medicine.
- 31 Aug 2021 Primary endpoint (change in alpha and beta diversity of the airway microbiome over 12 weeks between the ICS/LABA and LABA-only groups) has not been met, according to Results published in the American Journal of Respiratory and Critical Care Medicine.
- 31 Aug 2021 Results published in the American Journal of Respiratory and Critical Care Medicine.